Dr Tan Sing Huang is a Consultant Medical Oncologist with OncoCare Cancer Centre. Prior to entering private practice, she held the position of Senior Consultant in the Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS). She was also leading the Senior Residency Education division in NCIS as its Program Director since 2012 and successfully led the department in obtaining its initial American College of Graduate Medical Education-International (ACGME-I) accreditation in 2013 and once again its re-accreditation in 2015.
She was also Co-Chairman for the NCIS Clinical Competency Committee for the Senior Residency training and also previously panel member for National Interviews for selection of Medical Oncology trainees since 2014. She also contributed to undergraduate education as an Assistant Professor of the Yong Loo Lin School of Medicine, National University of Singapore and participated as an examiner for undergraduate final medical exams. As a result of her contributions to Education in the National University Hospital (NUH), she was awarded the NUH Teaching Excellence Award in 2014. Given her interest in continuing medical education, she has also helped to organize and served as Chairman of conferences such as the Best of ASCO in 2015 and co-organised the inaugural Breast Day Symposium in 2016.
She is the current Vice President of the Singapore Society of Oncology, a position she has held since 2013.
She is also a long-standing current active Committee Member of the National Healthcare Group Domain-Specific Ethics Review Board since 2011 which reviews Medical Oncology clinical trial protocols for academic institutions.
She is also a Workgroup Member for the College of Radiologists’ National Breast Cancer Screening Guidelines Review for 2017.
During her work at the National University Hospital Medical Oncology division since 2001, she had continued to take care of patients with a wide variety of cancers, including Breast cancers, Gynecological cancers, Lung cancers and Gastrointestinal cancers, although her primary interest is in Women’s Cancers. As a result of her clinical efforts in NUH, she was awarded the Sunny Side-Up and Sunny Side-Up WOW Awards for exemplary patient feedback.
She was also involved in clinical drug trials by being the principal investigator of several multi-center studies investigating new investigational drugs in HER2-positive breast cancers as well as being co-investigator of several multi-centre clinical trials in lung, colorectal and breast cancers.
She has maintained an interest in translational research during her oncology career which was further fostered by a fruitful training period spent at with the RUNX research group in Singapore under a National Medical Research-Singapore (NMRC) Totalisator Medical Research Fellowship Award in 2003-2004. She then went overseas to complete a postgraduate research fellowship at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Centre in Baltimore in 2006-2007 where she was involved in epigenetics research and also gained clinical experience from attachments with the Breast Cancer Division of Johns Hopkins Medical Institute.
Upon her return to Singapore, she was awarded the Research-Investigator-Scientist Enabler (RISE) Grant Scheme Award from 2008 to 2010, and also the Junior Investigator Protected Time Award in 2011.
She went on to obtain a Merit Award for her Oral Presentation at the 10th International Conference of The Asian Clinical Oncology Society in Seoul, Korea in 2012 on “High-throughput oncogenic mutation profiling changes pre- and post-chemotherapy in primary breast cancers”.
In order for her to spend more protected time in her research, she was given the National Medical Research Council Clinician Investigator Salary Support Program (CISSP) Award from 2012 to 2014.
She went on to obtain a number of independent grants since 2008 studying on various aspects such as methylation patterns in breast cancer, high-throughput oncogenic mutation profiling in breast cancers to chemotherapeutic regimens and clinical outcomes, and the effects of chemotherapy on cognition in cancer patients using PET scan imaging.
She has been invited to write chapters on chemotherapy treatment of metastatic breast cancer in the renowned international textbook Diseases of the Breast. In addition, she has written several articles published in international journals on the use of ovarian suppression in breast cancer, high throughput mutation profiling changes before and after chemotherapy, tumour gene expression profiling and pharmacogenetics in breast cancers, and promoter hypermethylation for RUNX3 and other tumor suppressor genes in nasopharyngeal carcinoma and various other solid tumours. She has also been involved in many research publications in international journals including those on the use of neoadjuvant doxorubicin and cyclophosphamide with or without sunitinib in breast cancer, pharmacogenetics-guided use of capecitabine in patients with advanced or metastatic tumours, dose modifications in Asian cancer patients receiving weekly docetaxel, and genotyping of human carbonyl reductase CBR3 with doxorubicin disposition and toxicity. These publications have appeared in several journals including Clinical Cancer Research and Annals of Oncology.
She has also given many local and overseas talks as an invited speaker including in China, Vietnam and Brunei. She has also given television interviews on Good Morning Singapore, and radio interviews on Mediacorp’s Body and Soul and Power 98 on cancer screening, cancer diagnosis and breast cancer.
She has had more than a decade of clinical experience in Medical Oncology and is fluent in English, Mandarin and Hokkien and is able to speak some Malay and Bahasa. She has taken care of patients from many regional and overseas regions including Indonesia, Vietnam, Myanmar, China, Bangladesh, Sri Lanka, India and Russia.